Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2009 Filed Nov 4, 2009 22:56 UTC |
COX CARRIE SMITHExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 400,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051073 · c91877_4x1.xml · derivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 400,000 shares Expires 2014-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:56 UTC |
COX CARRIE SMITHExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 375,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0001209191-09-051073 · c91877_4x1.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 375,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:56 UTC |
COX CARRIE SMITHExecutive Vice President
|
Disposition to issuerCommon Shares | 169,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051073 · c91877_4x1.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
Queisser Lori A.Senior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 40,100 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-09-051074 · c91854_4x1.xml · derivative · entry 5 Queisser Lori A. · CIK 0001390893 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,100 shares Expires 2016-04-30 F5 · price: Pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co., Inc., ("Merger Agreement"), upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
Queisser Lori A.Senior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 40,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001209191-09-051074 · c91854_4x1.xml · derivative · entry 4 Queisser Lori A. · CIK 0001390893 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2015-04-30 F5 · price: Pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co., Inc., ("Merger Agreement"), upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
Queisser Lori A.Senior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 65,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051074 · c91854_4x1.xml · derivative · entry 3 Queisser Lori A. · CIK 0001390893 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 65,000 shares Expires 2014-04-30 F5 · price: Pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co., Inc., ("Merger Agreement"), upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
Queisser Lori A.Senior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 120,000 | Not disclosed Strike: $23.24 | Not disclosed |
DisclosureSEC source: 0001209191-09-051074 · c91854_4x1.xml · derivative · entry 2 Queisser Lori A. · CIK 0001390893 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 120,000 shares Expires 2014-02-28 F5 · price: Pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co., Inc., ("Merger Agreement"), upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
Queisser Lori A.Senior Vice President
|
Disposition to issuerDeferred Stock Unit Award · Derivative | 10,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-09-051074 · c91854_4x1.xml · derivative · entry 1 Queisser Lori A. · CIK 0001390893 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit ("DSU") is the economic equivalent of one share of common stock. F3 · price: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan. F2 · derivative.exercise_date: The DSU's became vested upon the closing of the merger between the Issuer and Merck & Co., Inc. ("Merger"). F3 · derivative.expiration_date: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
VAN OORDT ROBERT FWDirector
|
Disposition to issuerStock Units · Derivative | 5,930.43 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051076 · c91876_4x0.xml · derivative · entry 3 VAN OORDT ROBERT FW · CIK 0001023222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,930.43 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
VAN OORDT ROBERT FWDirector
|
Disposition to issuerStock Equivalent Units · Derivative | 71,569.81 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051076 · c91876_4x0.xml · derivative · entry 2 VAN OORDT ROBERT FW · CIK 0001023222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 71,569.81 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:57 UTC |
VAN OORDT ROBERT FWDirector
|
Disposition to issuerCommon Shares | 31,749.77 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051076 · c91876_4x0.xml · nonDerivative · entry 1 VAN OORDT ROBERT FW · CIK 0001023222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerPhantom Stock Unit · Derivative | 62,117.06 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 8 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 62,117.06 shares Expires not disclosed F4 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F5 · price: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.exercise_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.expiration_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 177,000 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 7 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 177,000 shares Expires 2016-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 170,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 6 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 170,000 shares Expires 2015-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 200,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 5 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 200,000 shares Expires 2015-04-24 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 240,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 4 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 240,000 shares Expires 2014-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 250,000 | Not disclosed Strike: $17.37 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 3 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 250,000 shares Expires 2014-04-14 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 190,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · derivative · entry 2 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 190,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set for the in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
SABATINO THOMAS J JRExecutive Vice President
|
Disposition to issuerCommon Shares | 73,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051077 · c91856_4x1.xml · nonDerivative · entry 1 SABATINO THOMAS J JR · CIK 0001124182 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc., ("Merger") upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
TURNER KATHRYN CDirector
|
Disposition to issuerStock Units · Derivative | 23,590.36 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051078 · c91875_4x0.xml · derivative · entry 3 TURNER KATHRYN C · CIK 0001164641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,590.36 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
TURNER KATHRYN CDirector
|
Disposition to issuerStock Equivalent Units · Derivative | 6,474.27 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051078 · c91875_4x0.xml · derivative · entry 2 TURNER KATHRYN C · CIK 0001164641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,474.27 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:59 UTC |
TURNER KATHRYN CDirector
|
Disposition to issuerCommon Shares | 5,438.48 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051078 · c91875_4x0.xml · nonDerivative · entry 1 TURNER KATHRYN C · CIK 0001164641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerPhantom Stock Unit · Derivative | 65,587.15 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 9 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 65,587.15 shares Expires not disclosed F4 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F5 · price: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.exercise_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.expiration_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 130,100 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 8 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 130,100 shares Expires 2016-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 130,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 7 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 130,000 shares Expires 2015-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 130,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 6 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 130,000 shares Expires 2015-04-24 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 140,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 5 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 140,000 shares Expires 2014-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 4 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100,000 shares Expires 2014-02-22 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 45,000 | Not disclosed Strike: $15.27 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 3 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2013-10-31 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerOption (right to buy) · Derivative | 120,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 2 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 120,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
SAUNDERS BRENT LSenior Vice President
|
Disposition to issuerCommon Shares | 50,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051079 · c91857_4x1.xml · nonDerivative · entry 1 SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
STAHL JACK LDirector
|
Disposition to issuerStock Units · Derivative | 8,005.46 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051080 · c91874_4x0.xml · derivative · entry 2 STAHL JACK L · CIK 0001019427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,005.46 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:01 UTC |
STAHL JACK LDirector
|
Disposition to issuerCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051080 · c91874_4x0.xml · nonDerivative · entry 1 STAHL JACK L · CIK 0001019427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:03 UTC |
WEINBACH ARTHUR FDirector
|
Disposition to issuerStock Units · Derivative | 48,738.42 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051083 · c91870_4x0.xml · derivative · entry 3 WEINBACH ARTHUR F · CIK 0001198853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 48,738.42 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:03 UTC |
WEINBACH ARTHUR FDirector
|
Disposition to issuerStock Equivalent Units · Derivative | 30,556.86 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051083 · c91870_4x0.xml · derivative · entry 2 WEINBACH ARTHUR F · CIK 0001198853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,556.86 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:03 UTC |
WEINBACH ARTHUR FDirector
|
Disposition to issuerCommon Shares | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051083 · c91870_4x0.xml · nonDerivative · entry 1 WEINBACH ARTHUR F · CIK 0001198853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:04 UTC |
PEREZ ANTONIO MDirector
|
Disposition to issuerStock Units · Derivative | 8,005.46 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051085 · c91873_4x0.xml · derivative · entry 1 PEREZ ANTONIO M · CIK 0001226252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,005.46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F2 · price: Upon closing of the merger between the Issuer and Merck & Co., Inc., the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F2 · derivative.exercise_date: Upon closing of the merger between the Issuer and Merck & Co., Inc., the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F2 · derivative.expiration_date: Upon closing of the merger between the Issuer and Merck & Co., Inc., the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:04 UTC |
Colligan Thomas JDirector
|
Disposition to issuerStock Units · Derivative | 17,492.74 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051086 · c91871_4x0.xml · derivative · entry 3 Colligan Thomas J · CIK 0001295758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,492.74 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:04 UTC |
Colligan Thomas JDirector
|
Disposition to issuerStock Equivalent Units · Derivative | 2,890.44 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051086 · c91871_4x0.xml · derivative · entry 2 Colligan Thomas J · CIK 0001295758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,890.44 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:04 UTC |
Colligan Thomas JDirector
|
Disposition to issuerCommon Shares | 19,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051086 · c91871_4x0.xml · nonDerivative · entry 1 Colligan Thomas J · CIK 0001295758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:06 UTC |
MCGRATH EUGENE RDirector
|
Disposition to issuerStock Units · Derivative | 17,242.28 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051090 · c91872_4x0.xml · derivative · entry 3 MCGRATH EUGENE R · CIK 0001231700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,242.28 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:06 UTC |
MCGRATH EUGENE RDirector
|
Disposition to issuerStock Equivalent Units · Derivative | 27,863.41 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051090 · c91872_4x0.xml · derivative · entry 2 MCGRATH EUGENE R · CIK 0001231700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 27,863.41 shares Expires not disclosed F2 · derivative.exercise_price: Each unit is the economic equivalent of one share of common stock. F3 · price: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.exercise_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. F3 · derivative.expiration_date: Upon closing of the Merger, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 23:06 UTC |
MCGRATH EUGENE RDirector
|
Disposition to issuerCommon Shares | 23,526.06 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051090 · c91872_4x0.xml · nonDerivative · entry 1 MCGRATH EUGENE R · CIK 0001231700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 6 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2019-04-23 F2 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantStock Option (right to buy) · Derivative | 8,400 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 5 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,400 shares Expires 2018-02-28 F2 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $45.98 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 4 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-01-31 F2 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantRSU - Leader Shares · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 3 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2012-04-24 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantRSU - Leader Shares · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 2 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2011-05-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 5, 2009 23:58 UTC |
AMBROSE ADELE DV-P & Chief Com. Officer
|
GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051302 · c92124_4x0.xml · derivative · entry 1 AMBROSE ADELE D · CIK 0001182424 · V-P & Chief Com. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2011-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:01 UTC |
Kuhlik Bruce NExec. V.P. and General Counsel
|
GrantStock Option (right to buy) · Derivative | 72,800 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001209191-09-051303 · c92125_4x0.xml · derivative · entry 14 Kuhlik Bruce N · CIK 0001408181 · Exec. V.P. and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,800 shares Expires 2019-04-23 F3 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F3 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.